Singular Genomics Systems Inc (OMIC)
0.41
+0.01
(+2.35%)
USD |
NASDAQ |
Apr 26, 11:22
Singular Genomics Systems Cash from Operations (TTM): -73.65M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -73.65M |
| September 30, 2023 | -74.66M |
| June 30, 2023 | -79.64M |
| March 31, 2023 | -85.19M |
| December 31, 2022 | -87.09M |
| September 30, 2022 | -82.88M |
| June 30, 2022 | -72.07M |
| Date | Value |
|---|---|
| March 31, 2022 | -62.36M |
| December 31, 2021 | -51.70M |
| September 30, 2021 | -42.99M |
| June 30, 2021 | -38.68M |
| March 31, 2021 | -29.35M |
| December 31, 2020 | -24.87M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-87.09M
Minimum
Dec 2022
-24.87M
Maximum
Dec 2020
-61.93M
Average
-72.07M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
| Bruker Corp | 350.10M |
| Azenta Inc | 70.94M |
| Harvard Bioscience Inc | 14.03M |
| Bionano Genomics Inc | -125.18M |
| Akoya Biosciences Inc | -50.90M |